Hepatic metabolism of drugs

55 Ballatori N (1991) Mechanisms of metal transport across liver cell plasma membranes. Drug Metab Rev 23, 83–132. 56 Klaassen CD, Liu J (1998) Metallothionein transgenic and knock-out mouse models in the study of cadmium toxicity. J Toxicol Sci 23 (Suppl 2), 97–102. 57 Jacob ST, Ghoshal K, Sheridan JF (1999) Induction of metallothionein by stress and its molecular mechanisms. Gene Expr 7, 301–310. 58 Rodriguez-Moreno F, Gonzalez-Reimers E, Santolaria-Fernandez F et al. (1997) Zinc, copper, manganese, and iron in chronic alcoholic liver disease. Alcohol 14, 39–44. 59 Ran Q, Liang H, Gu M et al. (2004) Transgenic mice overexpressing glutathione peroxidase 4 are protected against oxidative stressinduced apoptosis. J Biol Chem 279, 55137–55146. 60 Imai H, Nakagawa Y (2003) Biological significance of phospholipid hydroperoxide glutathione peroxidase (PHGPx, GPx4) in mammalian cells. Free Radic Biol Med 34, 145–169. 61 Korotkov KV, Novoselov SV, Hatfield DL et al. (2002) Mammalian selenoprotein in which selenocysteine (Sec) incorporation is supported by a new form of Sec insertion sequence element. Mol Cell Biol 22, 1402–1411. 62 Baker SK (2005) Molecular clues into the pathogenesis of statinmediated muscle toxicity. Muscle Nerve 31, 572–580. 63 Kim H-Y, Gladyshev VN (2004) Methionine sulfoxide reduction in mammals: characterization of methionine-R-sulfoxide reductases. Mol Biol Cell 15, 1055–1064. 64 Korotkov KV, Kumaraswamy E, Zhou Y et al. (2001) Association between the 15-kDa selenoprotein and UDP-glucose:glycoprotein glucosyltransferase in the endoplasmic reticulum of mammalian cells. J Biol Chem 276, 15330–15336. 65 Beckett GJ, Arthur JR (2005) Selenium and endocrine systems. J Endocrinol 184, 455–465.

[1]  Wooin Lee,et al.  The orphan nuclear receptor HNF4α determines PXR- and CAR-mediated xenobiotic induction of CYP3A4 , 2003, Nature Medicine.

[2]  R. Kim,et al.  Nuclear receptors and drug disposition gene regulation. , 2005, Journal of pharmaceutical sciences.

[3]  C. Liddle,et al.  Predicting inductive drug-drug interactions. , 2003, Pharmacogenomics.

[4]  John T. Moore,et al.  CAR: detailing new models. , 2004, Trends in pharmacological sciences.

[5]  K. Byth,et al.  Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease , 1995, Hepatology.

[6]  R. Weinshilboum.  Inheritance and drug response. , 2003, The New England journal of medicine.

[7]  G. Wilkinson,et al.  Drug metabolism and variability among patients in drug response. , 2005, The New England journal of medicine.

[8]  T. Shimada,et al.  Immunohistochemical study of cytochrome P450 2C and 3A in human non-neoplastic and neoplastic tissues , 1999, Virchows Archiv.

[9]  L. Loeb,et al.  Environmental and chemical carcinogenesis. , 2004, Seminars in cancer biology.

[10]  B. Goodwin,et al.  Regulation of hepatic drug metabolism: role of the nuclear receptors PXR and CAR. , 2002, Seminars in liver disease.

[11]  C. Handschin,et al.  Regulatory network of lipid-sensing nuclear receptors: roles for CAR, PXR, LXR, and FXR. , 2005, Archives of biochemistry and biophysics.

[12]  D. Russell,et al.  Clinical importance of the cytochromes P450 , 2002, The Lancet.

[13]  J. Villeneuve,et al.  Cytochrome P450 and liver diseases. , 2004, Current drug metabolism.

[14]  U. Meyer,et al.  Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. , 2004, Pharmacogenetics.

[15]  G. Kullak-Ublick,et al.  Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. , 2005, Archives of biochemistry and biophysics.

[16]  Daniel C. Liebler,et al.  Elucidating mechanisms of drug-induced toxicity , 2005, Nature Reviews Drug Discovery.

[17]  W. Pierson,et al.  Altered theophylline clearance during an influenza B outbreak. , 1982, Pediatrics.

[18]  M. Ratain,et al.  Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[19]  E. Morgan.  Regulation of cytochrome p450 by inflammatory mediators: why and how? , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[20]  Magnus Ingelman-Sundberg,et al.  Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. , 2004, Trends in pharmacological sciences.

[21]  J. Whitlock,et al.  Induction of cytochrome P4501A1. , 1999, Annual review of pharmacology and toxicology.

[22]  S. Kliewer,et al.  Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. , 2002, Molecular pharmacology.

[23]  M. Huang,et al.  Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs , 2005, Clinical pharmacokinetics.

[24]  Urs A. Meyer,et al.  Pharmacogenetics – five decades of therapeutic lessons from genetic diversity , 2004, Nature Reviews Genetics.

[25]  Yuichi Sugiyama,et al.  Impact of Drug Transporter Studies on Drug Discovery and Development , 2003, Pharmacological Reviews.

[26]  P. Watkins,et al.  Pharmacogenetics and clinical gastroenterology. , 2003, Gastroenterology.

[27]  Munir Pirmohamed,et al.  The role of metabolic activation in drug-induced hepatotoxicity. , 2005, Annual review of pharmacology and toxicology.

[28]  B. Goodwin,et al.  The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. , 1999, Molecular pharmacology.

[29]  M. Fromm,et al.  Clinical aspects of the MDR1 (ABCB1) gene polymorphism. , 2004, Therapeutic drug monitoring.

[30]  D. Shen,et al.  Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. , 1997, Advanced drug delivery reviews.

[31]  S. Clarke,et al.  Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. , 2003, The Lancet. Oncology.